Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer.

Medicine (Baltimore) · 2025 · PMC12151043 · PMID 40489875

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although the difference in RFS between the 2 groups was not statistically significant (HR 1.311, 95% CI 0.848–2.025, P = .26), the high TLS group still showed a trend toward improved outcomes.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.